What is GPB Scientific?
Founded in 2002 and based in Carlsbad, CA, GPB Scientific is at the forefront of enabling a step-change in the purification and enrichment of cells for cell therapy production. The company has engineered a high-throughput, automatable, microfluidic closed-system designed for point-of-collection leukapheresis sample preparation for CAR-T therapy production. This proprietary system aims to eliminate labor-intensive manual enrichment steps, such as ficoll, direct magnetic, or centrifugation, which have been validated in lower-throughput applications. GPB Scientific's vision is to deliver a turnkey system capable of providing therapeutic dosing within seven days of collection, addressing critical bottlenecks in cell therapy manufacturing.
How much funding has GPB Scientific raised?
GPB Scientific has raised a total of $47.7M across 6 funding rounds:
Private Equity
$1.9M
Private Equity
$1.4M
Debt
$810K
Other Financing Round
$25.5M
Debt
$150K
Unspecified
$18M
Private Equity (2013): $1.9M, investors not publicly disclosed
Private Equity (2016): $1.4M, investors not publicly disclosed
Debt (2017): $810K, investors not publicly disclosed
Other Financing Round (2020): $25.5M featuring Vensana Capital and Amgen Business Development
Debt (2020): $150K backed by PPP
Unspecified (2021): $18M with participation from Vensana Capital Management and Amgen Ventures
Key Investors in GPB Scientific
Vensana Capital Management
Vensana Capital is a venture capital and growth equity investment firm focused on partnering with entrepreneurs to drive innovation in healthcare through medical technology. The firm invests in development and commercial stage companies across various sectors, including medical devices, diagnostics, digital health, and life science tools.
Amgen Ventures
Amgen Ventures is the corporate venture capital arm of Amgen, a leading biotechnology company. They invest in early-stage companies that are developing innovative technologies and therapeutics that align with Amgen's strategic interests in human therapeutics.
Amgen Business Development
Amgen Oncology is dedicated to transforming cancer treatment through innovative therapies and a commitment to patient care. With over 40 years of experience, the company focuses on delivering high-quality biosimilar medicines to enhance treatment options and promote a sustainable healthcare system.
What's next for GPB Scientific?
The substantial enterprise-level backing and recent strategic investment signal a strong vote of confidence in GPB Scientific's technology and market potential. This capital is poised to fuel the company's expansion, likely focusing on scaling production capabilities, further clinical validation, and broader market penetration. GPB Scientific's advancements in automating cell therapy workflows are critical for meeting the growing demand for these life-saving treatments, positioning the company for significant growth and impact in the biopharmaceutical sector. Future developments may include strategic partnerships and expanded product offerings to address diverse cell therapy modalities.
See full GPB Scientific company page
